OOIR: Observatory of International Research

Papers

(The TQCC of Drug Metabolism Reviews is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
The annoying flaws of gerontological research	42
Cell-Biomaterial constructs for wound healing and skin regeneration	41
Drug transporters in drug disposition – the year 2022 in review	30
Enantioselectivity in some physiological and pathophysiological roles of hydroxyeicosatetraenoic acids	28
Mechanisms of intestinal pharmacokinetic natural product-drug interactions	22
New strategy for rational use of antihypertensive drugs in clinical practice in high-altitude hypoxic environments	21
Differential modulation of cytochrome P450 enzymes by arsenicals in non-human experimental models	20
Cytochrome P450-mediated carbon-carbon bond formation in drug metabolism	19
An in-depth review of PPARγ modulators as anti-diabetes therapeutics	19
Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations	16
Multimolecular interactions from Chinese medicines activate nuclear receptor conformational changes: a potential strategy for anti-inflammatory therapy	14
Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special population	14
Biopolymers as promising vehicles for drug delivery to the brain	13
Drug transporters in drug disposition – highlights from the year 2024	13
Genetic determinants of paclitaxel-induced peripheral neuropathy: a review of current literature	13
A transcriptional regulatory network of HNF4α and HNF1α involved in human diseases and drug metabolism	12
Scaling factors to inform in vitro - in vivo extrapolation from preclinical and livestock animals: state of the field and recommendations	12
Metabolism of new drug modalities research advances – 2024 year in review	12
Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice	11
Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods	10
In silico ADME and target prediction studies of Alogliptin as drug molecule	10
Clinical pharmacokinetics of nebivolol: a systematic review	10
In-depth understanding of the structure-based reactive metabolite formation of organic functional groups	8
Impact of DNA methylation on ADME gene expression, drug disposition, and efficacy	8
Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs	8